USPSTF draft recommends breast screening start at age 40

The proposal, and where it landed

On May 9, 2023 the US Preventive Services Task Force opened public comment on a draft rule for breast cancer screening. The draft said all women should have a mammogram every other year, starting at age 40. Comment ran until June 5, 2023.

That was a change. Its earlier stance had left screening in the forties to personal choice, rather than urging it for all.

The same notice raised two open questions the Task Force called urgent. Does adding ultrasound or MRI help women with dense breasts and a normal mammogram? And what is the balance of good and harm in screening women over 75?

A draft is not a rule. This one was replaced by a final recommendation statement on April 30, 2024, and that final version is what stands now.

What the final statement says

The Task Force gave a B grade to a mammogram every two years for women aged 40 to 74. A B means it found at least moderate net benefit and advises the test.

For women 75 and older it gave an I statement. The evidence is too thin to weigh good against harm. It gave a second I statement for extra ultrasound or MRI in women with dense breasts and an otherwise clear mammogram. An I is not a vote against a test. It means the Task Force could not tell.

The rule covers cisgender women and everyone else assigned female at birth who is 40 or older and at average risk. That takes in women with dense breasts, and women whose parent, sibling, or child had breast cancer. It does not cover people with a high-risk gene change such as BRCA1 or BRCA2, or a history of high-dose radiation to the chest. Our overview of cancer screening explains what average risk means.

The benefit, in numbers

The Task Force does not only count trials. It also asks several research groups to model the same plan, then compares what they get.

Six models weighed screening every two years from 40 to 74 against the same schedule from 50 to 74. Starting ten years earlier averted a median of 1.3 extra breast cancer deaths per 1,000 women over a lifetime. Four models ran that test for Black women and found 1.8 extra deaths averted per 1,000.

The gap matters because the death rate is not equal. The statement puts the five-year age-adjusted breast cancer death rate at 27.6 per 100,000 among Black women and 19.7 per 100,000 among White women. That is roughly 40% higher.

The Task Force also cites a rise in the disease itself. Invasive breast cancer in women aged 40 to 49 rose an average of 2.0% a year between 2015 and 2019.

The harms, in the same units

Screening more people also finds more things that are not cancer, and some cancers that would never have caused trouble.

The models put screening every two years from 40 to 74 at 1,376 false-positive results per 1,000 women over a lifetime. A false positive is a result that looks odd but turns out not to be cancer. It usually means more imaging, sometimes a biopsy, and often weeks of worry. Our page on false-positive screening results covers what happens next.

Dropping the start age from 50 to 40 raises false positives by roughly 60%. It also adds about 2 overdiagnosed cases per 1,000 women over a lifetime, with a modeled range of 0 to 4.

Overdiagnosis means finding a cancer that would never have harmed a person or even shown up. You cannot spot it in one person. You can only estimate how often it happens across a group. Trials that met the Task Force's quality bar put it at roughly 11% to 19% of cancers found. Our page on overdiagnosis explains why the figure is so hard to pin down.

When to get checked

Screening is for people without symptoms. Symptoms need a different appointment, and they need it now, whatever your age or your last mammogram result:

• A new lump in the breast or armpit that does not resolve within one menstrual cycle
• Puckering, dimpling, or thickening of the skin over the breast
• A nipple that newly turns inward, or persistent scaling around it
• Spontaneous fluid from one nipple, especially blood-stained
• Swelling or redness affecting one breast only

For screening itself, the current federal benchmark is a mammogram every two years from age 40 to 74 for average-risk women.

What this does not mean

• This page describes a 2023 draft. The final statement of April 30, 2024 replaced it, and that is what applies now.
• The 1.3 deaths averted per 1,000 is a modeled lifetime median across six runs. It is not a measured trial result.
• "Not enough evidence" for extra imaging in dense breasts is not a finding that it fails. It is a finding that nobody yet knows.
• The Task Force is not the only body issuing guidance in the United States. Others set different ages and gaps between tests.
• None of this sets one person's plan. Risk, family history, and past findings all shift it, and that is a talk for a clinician.

Sources

• USPSTF, Public Comment on Draft Recommendation Statement, Draft Evidence Review, and Draft Modeling Report: Screening for Breast Cancer (May 9, 2023) — https://www.uspreventiveservicestaskforce.org/uspstf/announcements/public-comment-draft-recommendation-statement-draft-evidence-review-and-draft-modeling-report-screening-breast-cancer
• USPSTF, Final Recommendation Statement: Breast Cancer: Screening (April 30, 2024) — https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
• NCI, Breast Cancer—Patient Version — https://www.cancer.gov/types/breast

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.